In a 40-year-old woman with type 1 diabetes mellitus presenting with three months of non-bilious, food-containing vomiting and early satiety, normal vital signs and a soft, non-tender abdomen, what is the first-line pharmacologic therapy for her vomiting?

First-Line Pharmacologic Treatment for Diabetic Gastroparesis

Intravenous metoclopramide is the first-line pharmacologic treatment for this patient's vomiting due to diabetic gastroparesis. 1, 2

Clinical Presentation Confirms Gastroparesis

This patient's presentation is classic for diabetic gastroparesis in the setting of type 1 diabetes:

• Non-bilious vomiting containing undigested food indicates delayed gastric emptying rather than mechanical obstruction 1
• Early satiety and postprandial fullness are hallmark symptoms of gastroparesis 1, 3
• Three-month duration with type 1 diabetes strongly suggests diabetic gastroparesis, which occurs in 20-40% of patients with long-standing type 1 diabetes 1

Why Metoclopramide is First-Line

Metoclopramide is the only FDA-approved medication for gastroparesis treatment and combines dual mechanisms that directly address the pathophysiology: 1, 4

• Prokinetic effect through dopamine D2-receptor antagonism enhances gastric motility 5, 3
• Antiemetic effect directly relieves nausea and vomiting 5, 3
• Sustained efficacy demonstrated in placebo-controlled crossover trials, unlike other agents 5

Intravenous Route is Appropriate

Given the severity of symptoms (3 months of vomiting), IV administration should be initiated: 2

• Dose: 10 mg IV slowly over 1-2 minutes for diabetic gastroparesis 2
• IV therapy may be required up to 10 days before transitioning to oral administration 2
• Gastroparesis significantly impairs oral medication absorption, making IV route more reliable in severe cases 6

Why Other Options Are Incorrect

Ondansetron (5-HT3 antagonist) is second-line therapy reserved for patients who fail metoclopramide after 4 weeks of adequate trial 6, 7. It lacks prokinetic properties and only addresses nausea, not the underlying delayed gastric emptying. 3

Promethazine is not recommended in gastroparesis guidelines and lacks prokinetic effects. 1

Dexamethasone has no role in gastroparesis management and is not mentioned in any gastroparesis treatment guidelines. 1

Nortriptyline (tricyclic antidepressant) is an adjunctive agent for visceral pain and refractory nausea, not first-line therapy, and should only be considered after standard prokinetic therapy has been initiated. 1, 6, 8 Additionally, tricyclic antidepressants can worsen gastroparesis by impairing gastrointestinal motility through anticholinergic effects. 1

Critical Safety Monitoring

Monitor for extrapyramidal side effects including acute dystonic reactions, drug-induced parkinsonism, akathisia, and tardive dyskinesia: 1

• If acute dystonic reaction occurs, immediately administer diphenhydramine 50 mg IV 2
• FDA recommends against metoclopramide use beyond 12 weeks due to irreversible tardive dyskinesia risk 1
• Reserve for severe cases unresponsive to dietary modifications (low-fiber, low-fat, small frequent meals) 1

Treatment Algorithm After Initial Therapy

1. Weeks 0-4: IV metoclopramide 10 mg slowly over 1-2 minutes, transition to oral 5-10 mg three to four times daily (30 minutes before meals and bedtime) plus dietary modifications 6, 2
2. Weeks 4-8: If inadequate response, titrate oral metoclopramide up to 20 mg per dose (maximum 80 mg/day) 6
3. Week 8 onward: If metoclopramide fails or causes intolerable side effects, switch to domperidone 10 mg three times daily (requires FDA investigational drug application in the US) 1, 6
4. Adjunctive therapy: Add ondansetron 4-8 mg two to three times daily if nausea persists after adequate prokinetic trial 6, 7